We read with interest the Article by Gholamreza Roshandel and colleagues 1 on the effectiveness of the polypill, which showed significant reduction in major cardiovascular events in the polypill group compared with the placebo group. Nonetheless, clinicians must be careful when interpreting these findings. First, the proportion of patients with gastrointestinal bleeding in this study was similar in the polypill (0·4%) and placebo (0·3%) groups. However, the proportion of patients with gastrointestinal bleeding in the ARRIVE 2 trial was 0·97% and in the ASCEND 3 trial was 1·8%. Both these trials investigated the use of aspirin as a primary prevention strategy and excluded patients at a high risk of bleeding. This raises questions about whether patients in the study by Roshandel and colleagues 1 complied with the polypill prescription and whether gastrointestinal bleeding was underdiagnosed in the intervention group.
Second, more than 50% of the study participants had total cholesterol of more than 198 mg/dL and mean LDL cholesterol of 117 mg/dL. 1 The adjusted hazard ratio (HR) for major cardiovascular events in the polypill group was 0·66 (95% CI 0·55-0·80). 1 In the JUPITER trial, 4 participants had a mean LDL cholesterol of less than 130 mg/dL and the HR for major cardiovascular events was 0·48 (0·33-0·68) in the rosuvastatin group compared with the placebo group. Moreover, the meta-analysis by Zheng and Roddick 5 showed an HR of 0·89 (0·84-0·95) for major cardiovascular events with aspirin use in primary prevention. Hence, the effects on these events, including cardiovascular mortality, seem to be mostly (if not completely) related to
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We thank Simon Dimmitt and Hans Stampfer for their interest in our study of the effectiveness of a fourcomponent polypill for the prevention of cardiovascular diseases. 1 In clinical prac tice, atorvastatin doses range from 10 mg to 80 mg daily, and 20 mg per day is not considered a high dose. We tested the safety and efficacy of 20 mg atorvastatin in our pilot phase study 2 before using this dose in the main trial. Statins have a very good safety profile: placebo-controlled random ised trials have clearly shown that only a small proportion of adverse events thought to be attributed to statin therapy in clinical practice are actually caused by the statin, 3 and these drugs have been shown to decrease overall mortality in several long-term randomised trials. 3 In our study, too, the adjusted hazard ratio for overall mortality was 0·93 (95% CI 0·77-1·11).
We also thank Osama Dasa and Mohammed Ruzieh for their interest in our study. Low proportions of patients with gastrointestinal bleeding raises the possibility of either underdiagnosis or low compliance in the intervention group of our study. The trial included five gastroenterologists on its research team, excluded patients at medium and high risk of bleeding, and provided study participants with free access to a gastrointestinal endoscopy clinic at the study centre in Gonbad City, Iran. The team was especially interested in looking for gastrointestinal bleeding in all participants. Therefore, it is very unlikely that there was underdiagnosis of gastrointestinal bleeding in the intervention group. Compliance was measured using pill for which I wrote the accompanying editorial, 5 where only eight participants in the oral immunotherapy arm were recorded as having an SAE. By contrast, 52 participants had epinephrine administered; one participant needed three doses of epinephrine on a single occasion, and two participants needed epinephrine on six separate occasions. Of the 82 episodes of epinephrine administration, only two were deemed to be SAEs.
Oral immunotherapy clearly works in the majority of participants, but the journey is not without significant hazard. It is interesting to note how many studies have failed to measure its impact on quality of life, and the data on this that have emerged are not overly promising. count, which was the best possible method for this study. Regardless of the real compliance, the polypill was shown to be effective in reducing major cardiovascular events, and the safety profile was similar between the two study groups. We agree that both study groups had well controlled blood pressure at study baseline, which is probably because of the implementation of a rigorous cardiovascular disease surveillance programme in the Iranian public health network. 4 As a result of this programme, which has been ongoing for almost a decade, all individuals in our study received freeof-charge preventive services for blood pressure control. Polypill might indeed have stronger effects in reducing cardiovascular events in populations without similar preventive services. We also agree that statin and aspirin are two important components in our polypill that contributed to reducing cardiovascular events.
We developed the PolyIran Quality Control Program (PIQCP) tool to ensure that both trial groups received similar healthy lifestyle education. The PIQCP results showed that the quality of delivering lifestyle advice to the two study arms was almost the same. 5 We agree with the comment that the limitations of our trial and other studies considering polypill strategy should be carefully taken into account before recommending polypill for the general population.
Perception of severity of adverse events in oral immunotherapy
Derek Chu and colleagues 1 report on the discrepancy between the efficacy of peanut oral immunotherapy and the considerably increased risk of allergic and anaphylactic reactions during treatment. A further disconnect exists between what is formally designated a serious adverse event (SAE) and what a family would consider as such in real life. The former is defined as causing death, a life-threatening state, hospitalisation, disablility, congenital abnormality, or an event that necessitates intervention to prevent permanent impairment or damage. 2 An important medical event might be considered an SAE when, based on appropriate medical judgment, it could jeopardise the participant and might necessitate medical intervention to prevent one of the outcomes listed above. 3 A family is likely to perceive their use of an epinephrine autoinjector during an oral immunotherapy trial as fulfilling the latter, regardless of whether medical judgement is made by a trial study team as to its necessity. This was aptly demonstrated in by far the largest study to date, the PALISADE trial, 4
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We appreciate the opportunity to respond to Michael Perkin's queries about our study. 1 In medicine, large and well done randomised trials generate more trustworthy evidence about treatments than uncontrolled observations. 2,3 For any given clinical question, well done systematic reviews and meta-analyses provide the most credible information for decision
